• No.
• Generic Name
• Item
• Area
• Certification
• Note
• Structuer
• Purpose
• Inquiry

• 87
• Macitentan
• APIs & Intermediates
• Pulmonary Arterial Hypertension (PAH)

• USA

  -USDMF No. 031658

  Eu/ASMF 6 countries

  China

  -CDE Registration No.:Y20190000010

  WC to EU:ZJ240108
• 5 years stability
• 
• Inquiry

• 89
• Selexipag
• APIs & Intermediates
• Pulmonary arterial hypertension

• USA

  -ANDA No. 211026

  Tentative Approval

  China

  -CYHS1900599 Launched

  COPP:ZJ240108
• US DMF ready
• 
• Inquiry

• 125
• Rivaroxaban
• APIs & Intermediates
• Anti-Thrombosis
• Commercial
• patented process
• 
• Inquiry

• 154
• Macitentan premix pellet
• APIs & Intermediates
• Pulmonary Arterial Hypertension (PAH)
• non-infringing formulation
• Inquiry

• 155
• Selexipag
• APIs & Intermediates
• Pulmonary arterial hypertension
• Patented process(CN10482965B, US10144701B2, US10428012B2,cn106279047B, U10040771B2 )
• Inquiry

• 156
• Selexipag Premix pellet
• APIs & Intermediates
• Pulmonary arterial hypertension
• Ready for PV
• non-infringing polymorphism
• Inquiry

• 157
• Rivaroxaban
• APIs & Intermediates
• Anti-Thrombosis
• Commercial
• patented process
• 
• Inquiry

• 158
• Vortioxetine
• APIs & Intermediates
• Antidepressant

• USA

  -USDMF No. 038847

  China-CDE Registration No.:Y20230001182

• 4 years stability
• 
• Inquiry

• 159
• Vortioxetine
• APIs & Intermediates
• Antidepressant
• GC >99%
• Inquiry

• 162
• Semaglutide
• APIs & Intermediates
• Antidiabetic, weight reducing, hypotensive
• HPLC >98%, 10Kg/batch, 1000kg/year
• Inquiry

• 163
• Vortioxetine Premix pellet
• APIs & Intermediates
• Antidepressant
• PV done
• non-infringing polymorphism
• Inquiry